GARD®air.

The world’s first in vitro test for the prediction of chemical respiratory sensitizers

Sensitizing chemicals may induce sensitization of the respiratory tract, leading to symptoms known as occupational asthma.

GARDair, which is based on Artificial Intelligence and Genomics, enables not only development of safe products but also preventative measures – something that has not been feasible before.

There is currently a great need for tests in several different industries. GARDair, which was launched in the autumn of 2018, makes it possible to predict the risk of causing hypersensitivity with high reliability.

Using GARDair, it is possible not only to develop better and safer products, but also to be able to offer employees a safe production and work environment.

Interested in relevant results of your assays?

Find out more about the GARD concept in our product sheets or let our specialists explain the concept more thoroughly to you.

DOWNLOAD PRODUCT FACTS